NEW YORK (GenomeWeb News) – Compugen this week said that it has inked a deal to license to an unnamed diagnostic firm the biomarker candidate CGEN-226 for early detection of preeclampsia. Compugen used its in silico platform to identify the marker, which is a soluble splice variant of the vascular endothelial growth factor. (This brief has been corrected to state that Compugen licensed the biomarker to the unnamed partner rather than from the partner.)

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.